Cited by 1,091Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesCellular transport and secretion

Rational design and characterization of a Rac GTPase-specific small molecule inhibitor

Open access
Gao, Yuan, Dickerson, J. Bradley, Guo, Fukun, Zheng, Jie, Zheng, Yi·2004·Proceedings of the National Academy of Sciences

Abstract

The signaling pathways mediated by Rho family GTPases have been implicated in many aspects of cell biology. The specificity of the pathways is achieved in part by the selective interaction between Dbl family guanine nucleotide exchange factors (GEFs) and their Rho GTPase substrates. Here, we report a first-generation small-molecule inhibitor of Rac GTPase targeting Rac activation by GEF. The chemical compound NSC23766 was identified by a structure-based virtual screening of compounds that fit into a surface groove of Rac1 known to be critical for GEF specification. In vitro it could effectively inhibit Rac1 binding and activation by the Rac-specific GEF Trio or Tiam1 in a dose-dependent manner without interfering with the closely related Cdc42 or RhoA binding or activation by their respective GEFs or with Rac1 interaction with BcrGAP or effector PAK1. In cells, it potently blocked serum or platelet-derived growth factor-induced Rac1 activation and lamellipodia formation without affecting the activity of endogenous Cdc42 or RhoA. Moreover, this compound reduced Trio or Tiam1 but not Vav, Lbc, Intersectin, or a constitutively active Rac1 mutant-stimulated cell growth and suppressed Trio, Tiam1, or Ras-induced cell transformation. When applied to human prostate cancer PC-3 cells, it was able to inhibit the proliferation, anchorage-independent growth and invasion phenotypes that require the endogenous Rac1 activity. Thus, NSC23766 constitutes a Rac-specific small-molecule inhibitor that could be useful to study the role of Rac in various cellular functions and to reverse tumor cell phenotypes associated with Rac deregulation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0307512101

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [32]Lyons, L. S., Krajewski, S. K., Welsh, C. & Burnstein, K. L. (2003) Proc. Am. Assoc. Cancer Res. 44, 273 (R1404).
  2. [40]Kato-Stankiewicz, J., Hakimi, I., Zhi, G., Zhang, J., Serebriiskii, I., Guo, L., Edamatsu, H., Koike, H., Menon, S., Eckl, R., et al. (2002) Proc. Natl. Acad. Sci. USA 99, 14398-13303.

Cited by

Sorted by citations

Authors
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y.
Affiliations
St. Jude Children's Research Hospital (US)
Corresponding author
Zheng, Yi
Venue
Proceedings of the National Academy of Sciences
Published
2004-05-05
Volume
101
Issue
20
Pages
7618-7623
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2142685635
Cited by
1,091
References
1
Citations by year
2026: 22 · 2025: 26 · 2024: 28 · 2023: 31 · 2022: 39 · 2021: 48 · 2020: 43 · 2019: 36 · 2018: 42 · 2017: 52 · 2016: 56 · 2015: 57 · 2014: 66 · 2013: 71 · 2012: 70
FWCI
12.40
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • University of North Carolina at Chapel Hill
  • National Institute of General Medical Sciences (R01GM060523, R01GM053943, R01GM069916, GM53943, GM-60523, GM61739, R01GM061739)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords
Rac GTPase, small molecule inhibitors, NSC23766, trios, Tiam1, Rho GTPases, structure-based virtual screening, Rac1 activation, lamellipodia formation, platelet-derived growth factor, cell transformation, prostate cancer, tumor invasion, anchorage-independent growth
MeSH terms
Aminoquinolines, Humans, Male, Phenotype, Prostatic Neoplasms, Pyrimidines, Tumor Cells, Cultured, Protein Structure, Tertiary, rac GTP-Binding Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review